

ASX Announcement

Novel preclinical data published in *Cancer Research* highlighting Zantrene's potential in colorectal and pancreatic cancers

- Two abstracts published in *Cancer Research* by research collaborators of Race's Scientific Advisory Board Member, Prof Chen have further highlighted Zantrene's use as a targeted inhibitor of FTO and anti-cancer agent.
- The first abstract demonstrates Zantrene's ability to target FTO in the suppression of pancreatic cancer.
- The second abstract discusses the potential use of Zantrene as an adjunctive treatment to 5-FU based chemotherapy for colorectal cancer patients.
- These results add to Race's own reported preclinical and clinical data showing Zantrene's potential in targeting FTO in AML, melanoma and kidney cancer.

21 June 2022 – Race Oncology Limited ("Race") is pleased to announce that two peer reviewed research poster abstracts detailing new preclinical data on the anti-cancer uses of Zantrene (also known as bisantrene or CS1) have been published in the prestigious scientific journal, *Cancer Research*, following their recent presentation at the American Association of Cancer Research (AACR) Annual Conference in New Orleans, from April 8 – 13, 2022.

The two posters were presented by researchers from the City of Hope Hospital and Chicago University, including Race's Scientific Advisory Board member, Professor Jianjun Chen. They describe the use of Zantrene as a potent inhibitor of FTO – the Fat Mass and Obesity-associated protein.

The first abstract describes preclinical data demonstrating Zantrene's ability to inhibit FTO and suppress pancreatic carcinogenesis via targeting cancer stem cell maintenance. Pancreatic cancer has few effective treatment options and patients need better treatments for this devastating disease.

The second abstract explores the use of Zantrene as an adjunctive treatment able to overcome colorectal cancer resistant to 5-FU based chemotherapy via inhibition of FTO in both cell and mouse models. Resistance to 5-FU is a significant clinical issue as this drug remains a backbone of colorectal cancer treatment.

This important research exploring Zantrene utility in pancreatic cancer and colorectal cancer complements Race's own recent findings that Zantrene can inhibit FTO in AML, melanoma and clear cell renal cell carcinoma.

Summary of Abstracts

Abstract 5711: *Targeting FTO suppresses pancreatic carcinogenesis via cancer stem cell maintenance*

Authors: Rachana Garg, Laleh Melstorm, Jianjun Chen, Chuan He, Ajay Goel.
doi.org/10.1158/1538-7445.AM2022-5717

“Conclusion: Through a comprehensive mechanistic analysis we explicitly demonstrate the biological and functional significance of FTO in governing PC [pancreatic cancer] tumorigenesis and maintenance of CSC; thus, targeting FTO may represent an attractive therapeutic approach for PC.”

Abstract 5717: *Novel evidence for FTO as an oncogenic player and mediator of chemoresistance in colorectal cancer*

Authors: Rachana Garg, Laleh Melstorm, Jianjun Chen, Chuan He, Ajay Goel.
doi.org/10.1158/1538-7445.AM2022-5711

“Conclusion: Our study establishes the functional importance of FTO in CRC [colorectal cancer] and provides novel evidence for the potential use of FTO inhibitor as an adjunctive treatment to 5FU based chemotherapy for CRC patients.”

Race Chief Scientific Officer, Dr Daniel Tillet said: *“This very promising research further highlights the emergence of Zantrene as an exquisitely potent inhibitor of FTO – one of the central genes in the proliferation of many cancers. We are excited to see interest and use of Zantrene build, thanks to the efforts of great researchers like our collaborator Professor Chen and his colleagues.”*

-ENDS-

About Race Oncology (ASX: RAC)

Race Oncology is an ASX listed precision oncology company with a Phase 2/3 cancer drug called Zantrene®.

Zantrene is a potent inhibitor of the Fatso/Fat mass and obesity associated (FTO) protein. Overexpression of FTO has been shown to be the genetic driver of a diverse range of cancers. Race is exploring the use of Zantrene as a new therapy for melanoma and clear cell renal cell carcinoma, which are both frequent FTO over-expressing cancers.

In breakthrough preclinical research, Race has also discovered that Zantrene protects from anthracycline-induced heart damage, while in tandem acting with anthracyclines and proteasome inhibitors to improve their ability to target breast cancer. Race is evaluating this discovery.

The Company also has compelling clinical data for Zantrene as a chemotherapeutic agent and is in clinical trial in Acute Myeloid Leukaemia (AML).

Race is pursuing outsized commercial returns for shareholders via its 'Three Pillar' strategy for the clinical development of Zantrene.

Learn more at www.raceoncology.com

Release authorised by:

Phil Lynch, CEO/MD on behalf
of the Race Board of Directors
phillip.lynch@raceoncology.com

Media contact:

Jane Lowe
+61 411 117 774
jane.lowe@irdepartment.com.au